1-(甲基磺酰基)-1,4-二氮杂烷盐酸盐 | 550369-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 中文名称: 1-(甲基磺酰基)-1,4-二氮杂烷盐酸盐
• 英文名称: 1-(Methylsulfonyl)-1,4-diazepane
• 英文别名: 1-methylsulfonyl-1,4-diazepane
• CAS: 550369-26-1
• 化学式: C₆H₁₄N₂O₂S
• mdl: MFCD08444716
• 分子量: 178.26
• InChiKey: HWXMTJPGLBLECG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• N-BENZYL PYRROLIDINE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20100113424A1

  公开（公告）日：2010-05-06

  The present invention relates to a compound of formula I wherein Ar, R 1 , R 2 , R 3 , n, and o are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下式I的化合物，其中Ar、R1、R2、R3、n和o如本文所定义，或者涉及其药用活性盐、消旋混合物、对映体、光学异构体或其互变异构体。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS
  申请人：Knust Henner

  公开号：US20080312216A1

  公开（公告）日：2008-12-18

  The present invention relates to a compound of formula I wherein R 1 , R 2 , R 3 , R 4 , R 9 , R 10 , m and n are as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, bipolar disorders, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有如下式I的化合物，其中R1、R2、R3、R4、R9、R10、m和n如本文所定义，或其药学上可接受的酸盐。本化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、双相情感障碍、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意缺陷多动障碍（ADHD）。
• [EN] N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS<br/>[FR] DÉRIVÉS DE N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL) PYRIMIDIN-2-AMINE UTILISÉS COMME COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV SOUTH AUSTRALIA

  公开号：WO2017020065A1

  公开（公告）日：2017-02-09

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:

  这是一类新型的蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病况，特别是那些表现为CDK4、CDK6和/或cyclin D过度表达的疾病，包括肺癌、乳腺癌、脑部、中枢神经系统、结肠直肠癌和白血病等。这些抑制剂具有一般式I的结构。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。